Upload Records Snowball Search Search OpenAlex
About the database ScholarIQanswers from OpenAlex
Lung Cancer Treatments and Mutations
TopicLeading institutions, researchers & key papers
This cluster of papers focuses on the advancements in lung cancer research, particularly in understanding EGFR and ALK mutations, targeted therapy, resistance mechanisms to tyrosine kinase inhibitors, clinical trials evaluating different treatment regimens, genomic profiling for personalized medicine, and the development of treatment guidelines based on molecular biomarkers. The research also explores the concept of oncogene addiction and its implications for targeted therapies.
131,861
Works
1,712,980
Citations
IDs:OpenAlex
How has Lung Cancer Treatments and Mutations's publication output changed over time?
ScholarIQpublication output · 2009–2019
Output grew0% over the shown period — from 1 works in 2009 to 1 in 2019.
1
1
1
1
2009201420182019
Who are the most-cited researchers behind Lung Cancer Treatments and Mutations?
ScholarIQtop researchers by citations
What are the most-cited papers on Lung Cancer Treatments and Mutations?
ScholarIQmost cited works
Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC
Mark A. Socinski, Robert M. Jotte, Federico Cappuzzo, Francesco Orlandi, Daniil Stroyakovskiy, Naoyuki Nogami, Delvys Rodríguez‐Abreu, Denis Moro‐Sibilot, Christian A. Thomas, Fabrice Barlési, Gene Grant Finley, Claudia Kelsch, Anthony Lee, Shelley Coleman, Yu Deng, Yijing Shen, Marcin Kowanetz, Ariel López-Chávez, Alan Sandler, Martin Reck
New England Journal of Medicine. 20183,770 CitationsOPEN ACCESS
First-Line Crizotinib versus Chemotherapy in <i>ALK</i>-Positive Lung Cancer
Benjamin Solomon, Tony Mok, Dong‐Wan Kim, Yi‐Long Wu, Kazuhiko Nakagawa, Tarek Mekhail, Enriqueta Felip, Federico Cappuzzo, Jolanda Paolini, Tiziana Usari, Shrividya Iyer, Arlene Reisman, Keith D. Wilner, Jennifer Tursi, Fiona Blackhall
New England Journal of Medicine. 20143,219 CitationsOPEN ACCESS
Screening for Epidermal Growth Factor Receptor Mutations in Lung Cancer
Rafael Rosell, Teresa Morán, Cristina Queralt, Rut Porta, Felipe Cardenal, Carlos Camps, Margarita Majem, Guillermo López-Vivanco, Dolores Isla, Mariano Provencio, Amelia Insa, Bartomeu Massutí, J.L. González-Larriba, Luis Paz‐Ares, Isabel Bover, Rosario García‐Campelo, Miguel Ángel Moreno, Sílvia Catot, Christian Rolfo, Noemı́ Reguart, Ramón Palmero, José Miguel Sánchez, Roman Bastus, Clara Mayo, Jordi Bertran-Alamillo, Miguel Ángel Molina‐Vila, José Javier Sánchez, Miquel Tarón
New England Journal of Medicine. 20092,381 CitationsOPEN ACCESS
Non–Small Cell Lung Cancer: Epidemiology, Screening, Diagnosis, and Treatment
Narjust Duma, Rafael Santana-Dávila, Julian R. Molina
Mayo Clinic Proceedings. 20192,251 Citations
Where is Lung Cancer Treatments and Mutations research published, and who funds it?
ScholarIQvenues & funding sources
TOP JOURNALS
TOP FUNDERS
National Science Foundation—
NIH—
Wellcome Trust—
European Research Council—
Funder breakdown is a member featureSign up free to unlock
How much of the research on Lung Cancer Treatments and Mutations is open access?
ScholarIQopen access share
75%OPEN ACCESS
Gold
0%
Green
0%
Hybrid
25%
Bronze
50%
Closed
25%
Who collaborates most closely around Lung Cancer Treatments and Mutations?
ScholarIQco-authorship network
United States
92%
India
8%